Nautilus Biotechnology, Inc. NAUT
Set alert
2.34 USD -0.40 -14.47%
At close
2.36 +0.03 +1.11%
Pre-market · Nov 3, 5:19 AM ET
2.27 Day range 2.75
0.841 52-week range 4.31
- YTD
- +19.74%
- 1 year
- +75.56%
- Open
- 2.74
- Prev close
- 2.73
- Mkt cap
- 297.41M
- Vol
- 7.30M
- Avg vol
- 5.35M
- EPS
- -0.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.27
- High
- 2.75
- Forward P/E
- -2.32
- Beta
- 1.04
- Short ratio
- 9.26
- Inst. own
- 50.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 30, 2024
- 50-d avg
- 2.42
- 200-d avg
- 2.56
- 1y target
- 3.44
5m chart
Built from the cached five-day intraday bars.
Signals (98)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 2:35 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 1:40 PM | 15 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 11:45 AM | 17 hours ago |
| SMA: Bearish | Nov 2, 11:45 AM | 17 hours ago |
| SMA: Bullish | Nov 2, 11:40 AM | 17 hours ago |
| SMA: Bullish | Nov 2, 11:15 AM | 18 hours ago |
| MACD: Buy Signal | Nov 2, 11:15 AM | 18 hours ago |
| MACD: Sell Signal | Nov 2, 10:40 AM | 18 hours ago |
| SMA: Bearish | Nov 2, 10:35 AM | 18 hours ago |
| MACD: Buy Signal | Nov 2, 10:25 AM | 19 hours ago |
| SMA: Bullish | Nov 2, 10:05 AM | 19 hours ago |
| RSI: Oversold | Nov 2, 9:35 AM | 19 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 20 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 20 hours ago |
| MACD: Sell Signal | Nov 2, 9:30 AM | 20 hours ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:40 PM | 3 days ago |
Newest 20 of 98.
Key statistics
- Market cap
- 215.97M
- Enterprise value
- 111.95M
- Trailing P/E
- 0.00
- Forward P/E
- -2.32
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.97
- EPS (TTM)
- -0.56
- Beta
- 1.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -35.00M
- Total cash
- 140.61M
- Total debt
- 31.57M
- Return on equity
- -28.04%
- Shares outstanding
- 125.56M
- Short % of float
- 2.81%
- 50-day average
- 2.42
- 200-day average
- 2.56
Analyst view
Consensus: buy
Buy
Price target (mean) 3.44 +47.2% upside
Now 2.34
- Target (low)
- 1.75
- Target (mean)
- 3.44
- Target (high)
- 5.00
Ratings (0m) 5 2 buy · 2 hold · 1 sell
- Strong buy0
- Buy2
- Hold2
- Sell0
- Strong sell1
Next earnings
Jul 30, 2024
Expected Jul 30, 2024. Consensus EPS estimate -0.16333.
Financials — quick view
NAUT Revenue — quarterly 234.00K
NAUT Net income — quarterly -15.64M
NAUT EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2024 | Sep 1, 2024 | -0.17 | -0.13 | +0.04 | +23.53% |
| Jul 30, 2024 | Jun 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| Jul 30, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.16 | -0.15 | +0.01 | +6.25% |
| Apr 30, 2024 | Mar 1, 2024 | -0.16 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.16 | -0.14 | +0.02 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Goldman Sachs | down | Neutral | Sell |
| Jun 27, 2024 | Guggenheim | init | — | Buy |
| Aug 3, 2023 | Morgan Stanley | reit | Equal-Weight | Equal-Weight |
| Aug 3, 2022 | Morgan Stanley | main | — | Equal-Weight |
| Aug 3, 2022 | Goldman Sachs | main | — | Neutral |
| Jul 14, 2022 | Goldman Sachs | main | — | Neutral |
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nautilus.bio
News
- Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch
- Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
- Nautilus Biotechnology Q3 Earnings Call Highlights
- Nautilus Biotechnology Q3 2026 Earnings Call Transcript
- Nautilus Biotechnology Announces Participation In SEEDS Research Consortium, Which Was Awarded Up To $51.7M By The Advanced Research Projects Agency For Health
- Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
- Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on NAUT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GODWIN MARY E | Officer | Conversion of Exercise of derivative security | Sep 22, 2024 | 0 |
| PATEL SUJAL M | Chief Executive Officer | Purchase | Mar 10, 2024 | 17,159,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ah Capital Management, L.L.C. | 14.06% | 17,653,917 | 30.36M | Sep 29, 2024 |
| Perceptive Advisors Llc | 10.03% | 12,594,211 | 21.66M | Sep 29, 2024 |
| Cercano Management Llc | 5.71% | 7,172,985 | 12.34M | Sep 29, 2024 |
| Madrona Venture Group, LLC | 4.79% | 6,020,770 | 10.36M | Sep 29, 2024 |
| Blackrock Inc. | 2.84% | 3,565,243 | 6.13M | Sep 29, 2024 |
| Vanguard Group Inc | 2.20% | 2,766,343 | 4.76M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.39% | 1,745,090 | 3.00M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.96% | 1,202,875 | 2.07M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 670,132 | 1.15M | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.41% | 519,943 | 894.30K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.39% | 491,428 | 845.26K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.35% | 433,685 | 745.94K | Oct 30, 2024 |